Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Controlled Placebo Clear all
Completed Phase 2 Interventional Results available

RZL-012 for Dercum's Disease Lipomas

NCT04229030
View directory record Official record
Conditions
Dercum's Disease Lipomas
Interventions
RZL-012, Vehicle
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

NCT05411367
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SI-614, Placebo
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

NCT03431610
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
SB414 2%, SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

NCT02309385
View directory record Official record
Conditions
Non-Infectious Anterior Uveitis
Interventions
8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops
Drug
Lead sponsor
Aciont Inc
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

NCT02952898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • San Ramon, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris

NCT00525499
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ASC-J9 cream, placebo
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Fremont, California • San Diego, California • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Cantharidin Application in Molluscum Patients-1

NCT03377790
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
18
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

NCT02014376
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

NCT01155362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty

NCT02525133
View directory record Official record
Conditions
Pain, Postoperative
Interventions
XaraColl, Placebo
Drug · Other
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
24
States / cities
Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

NCT04739709
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Scottsdale, Arizona • Glendale, California • Hemet, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

NCT01769755
View directory record Official record
Conditions
Crohns Disease
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

NCT00763555
View directory record Official record
Conditions
Psoriasis
Interventions
CD 2027, Calcitriol Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Fridley, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

NCT04050865
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone, 0.4mg, Placebo plug with no drug
Drug · Device
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Colorado Springs, Colorado • Louisville, Kentucky • Raynham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

NCT03727022
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Placebo, SM04690
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Canoga Park, California • Carmichael, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

NCT05244980
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

NCT02933879
View directory record Official record
Conditions
Onychomycosis
Interventions
NVXT topical, Placebo (Vehicle) Topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

NCT01134705
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
35
States / cities
Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of STP206 in Healthy Adult Subjects

NCT00922324
View directory record Official record
Conditions
Healthy
Interventions
STP206 or vehicle control
Drug
Lead sponsor
Leadiant Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

NCT02874846
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 26, 2026, 2:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

NCT01986920
View directory record Official record
Conditions
Seborrheic Keratosis (SK)
Interventions
A-101 25%, A-101 32.5%, A-101 40%, A-101 Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 26, 2026, 2:07 PM EDT